Abvc biopharma announces pricing of $1.75 million registered direct offering

Fremont, ca, july 27, 2023 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today announced it has entered into a definitive securities purchase agreement with a single institutional investor to purchase $1.75 million worth of its common stock in a registered direct offering (the “offering”).
ABVC Ratings Summary
ABVC Quant Ranking